POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES.

X. Baraliakos, A. Deodhar, D. Van der Heijde, M. Magrey, W. P. Maksymowych, T. Tomita, H. Xu, M. Oortgiesen, U. Massow, C. Fleurinck, A. Ellis, T. Vaux, J. Smith, A. Marten, L. S. Gensler. POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 2023 May 30; 82(Suppl 1):873.2-874.

2023
https://researcherprofiles.org/profile/425025837

X. Baraliakos, A. Deodhar, D. Van der Heijde, M. Magrey, W. P. Maksymowych, T. Tomita, H. Xu, M. Oortgiesen, U. Massow, C. Fleurinck, A. Ellis, T. Vaux, J. Smith, A. Marten, L. S. Gensler